Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Weiyan Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8183-9497; OpenAlex author ID A5005088423. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. Synergistic Enhancement of Immunogenic Cell Death Through Photothermal/Photodynamic Effects via Complex Nanoenzymes for Pancreatic Cancer Therapy. Last author DOI 10.1002/adhm.202505709↗
  2. Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression. Last author DOI 10.1007/s10528-025-11186-0↗
  3. MicroRNA-130b Suppresses Malignant Behaviours and Inhibits the Activation of the PI3K/Akt Signaling Pathway by Targeting MET in Pancreatic Cancer. Last author DOI 10.1007/s10528-024-10696-7↗
  4. Contribution of a Circulating 2'-O-methylated MicroRNA Panel to the Diagnosis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.91716↗
  5. Exosomal miR-19a decreases insulin production by targeting Neurod1 in pancreatic cancer associated diabetes. Co-author DOI 10.1007/s11033-021-06980-z↗
  6. Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2. First author DOI 10.7150/ijbs.56271↗
  7. MicroRNA-221-3p is related to survival and promotes tumour progression in pancreatic cancer: a comprehensive study on functions and clinicopathological value. Last author DOI 10.1186/s12935-020-01529-9↗
  8. Effect of p53 on pancreatic cancer-glucose tolerance abnormalities by regulating transglutaminase 2 in resistance to glucose metabolic stress. Co-author DOI 10.18632/oncotarget.19402↗
  9. MicroRNA-148a Suppresses the Proliferation and Migration of Pancreatic Cancer Cells by Down-regulating ErbB3. Last author DOI 10.1097/mpa.0000000000000677↗
  10. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. Co-author DOI 10.1111/1753-0407.12313↗
  11. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. Co-author DOI 10.1159/000447872↗
  12. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Last author DOI 10.1111/cas.12747↗
  13. Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer. Last author DOI 10.3892/ol.2014.2429↗
  14. Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Co-author DOI 10.1111/cas.12107↗
  15. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗
  16. Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Co-author DOI 10.1016/j.canlet.2011.03.011↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xuejiao Wu · 4 shared papers, 2020–2026 · strength 1.03
  2. Zilin Yang · 4 shared papers, 2020–2026 · strength 1.03
  3. Jiancheng Wang · 2 shared papers, 2020–2025 · strength 0.45
  4. Wenjing Pang · 4 shared papers, 2015–2022 · strength 0.42
  5. Xin Dai · 4 shared papers, 2015–2022 · strength 0.42
  6. Yaozong Yuan · 7 shared papers, 2011–2017 · strength 0.33
  7. Lei Li · 2 shared papers, 2021–2022 · strength 0.31
  8. Jiaojiao Su · 3 shared papers, 2015–2022 · strength 0.30
  9. Yinxun Jin · 1 shared paper, 2026 · strength 0.29
  10. Baiwen Li · 1 shared paper, 2024 · strength 0.22
  11. Cheng Wang · 3 shared papers, 2012–2016 · strength 0.14
  12. Xiangjun Meng · 1 shared paper, 2021 · strength 0.13
  13. Yongping Zhang · 1 shared paper, 2020 · strength 0.13
  14. Hui Feng · 2 shared papers, 2015–2016 · strength 0.12
  15. Xiangyi He · 2 shared papers, 2014–2017 · strength 0.11
  16. Rui Liu · 2 shared papers, 2012–2016 · strength 0.09
  17. Yi Ba · 2 shared papers, 2012–2016 · strength 0.09
  18. Hongwei Liang · 1 shared paper, 2016 · strength 0.07
  19. Xiao Hua Su · 1 shared paper, 2017 · strength 0.06
  20. Ping Chen · 1 shared paper, 2017 · strength 0.06
  21. Qiwen Ben · 1 shared paper, 2017 · strength 0.06
  22. Wei‐Guang Li · 1 shared paper, 2017 · strength 0.06
  23. Yi Zang · 1 shared paper, 2017 · strength 0.06
  24. Ting Deng · 1 shared paper, 2016 · strength 0.06
  25. Lu Xia · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.